Parabilis Medicines, Inc. (PBLS)Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
29.63 USD
-0.94
(-3.075%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 29.06 -0.57 (-0.570%) ⇩ (July 13, 2026, 6:49 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:08 a.m. EDT
The immediate outlook is neutral due to the lack of a clear directional edge in the recent price action, which has oscillated within a tight range since the IPO. While the company boasts a fortress-like balance sheet with a massive cash pile relative to its tiny debt load and a current ratio exceeding 6, these defensive attributes are typical of early-stage biotechs rather than catalysts for immediate equity appreciation. The absence of any dividend income eliminates income potential entirely. Looking further ahead, the investment case remains speculative; despite a 'strong buy' analyst consensus and insider purchases signaling confidence in the long-term mission, the company lacks a proven revenue track record or positive earnings history. Without multi-year price data to confirm a sustainable growth trajectory, the market cannot yet validate the business quality, leaving the long-term rating neutral until the pipeline delivers tangible commercial results. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 21.762 |
| Market Cap | 3,624,117,760 |
| Forward P/E | -15.59 |
| Website | https://parabilismed.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.03259492 |
| Address1 | 30 Acorn Park Drive |
| All Time High | 34.47 |
| All Time Low | 24.51 |
| Ask | 29.66 |
| Ask Size | 1 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 489,930 |
| Average Daily Volume3 Month | 1,114,880 |
| Average Volume | 1,114,880 |
| Average Volume10Days | 489,930 |
| Bid | 29.53 |
| Bid Size | 1 |
| Book Value | -174.149 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 29.63 |
| Current Ratio | 6.122 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 30.375 |
| Day Low | 28.68 |
| Debt To Equity | 21.762 |
| Display Name | Parabilis Medicines |
| Ebitda | -153,666,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -4.137 |
| Enterprise Value | 635,683,456 |
| Eps Current Year | -1.66 |
| Eps Forward | -1.9 |
| Eps Trailing Twelve Months | -1.77 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 28.351904 |
| Fifty Day Average Change | 1.2780952 |
| Fifty Day Average Change Percent | 0.045079697 |
| Fifty Two Week Change Percent | -3.259492 |
| Fifty Two Week High | 34.47 |
| Fifty Two Week High Change | -4.840002 |
| Fifty Two Week High Change Percent | -0.140412 |
| Fifty Two Week Low | 24.51 |
| Fifty Two Week Low Change | 5.119999 |
| Fifty Two Week Low Change Percent | 0.20889428 |
| Fifty Two Week Range | 24.51 - 34.47 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,781,098,200,000 |
| Float Shares | 2,489,747 |
| Forward Eps | -1.9 |
| Forward P E | -15.594737 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 145 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03778 |
| Held Percent Institutions | 0.54109 |
| Implied Shares Outstanding | 122,312,446 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,026-06-10 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts. |
| Long Name | Parabilis Medicines, Inc. |
| Market | us_market |
| Market Cap | 3,624,117,760 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_316822253 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -209,706,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 3,739,091,473 |
| Number Of Analyst Opinions | 4 |
| Open | 30.35 |
| Operating Cashflow | -138,759,008 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | (617) 945-9510 |
| Post Market Change | -0.5699997 |
| Post Market Change Percent | -1.923725 |
| Post Market Price | 29.06 |
| Post Market Time | 1,783,982,969 |
| Previous Close | 30.57 |
| Price Eps Current Year | -17.849398 |
| Price Hint | 2 |
| Price To Book | -0.17014165 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.066 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.940001 |
| Regular Market Change Percent | -3.07491 |
| Regular Market Day High | 30.375 |
| Regular Market Day Low | 28.68 |
| Regular Market Day Range | 28.68 - 30.375 |
| Regular Market Open | 30.35 |
| Regular Market Previous Close | 30.57 |
| Regular Market Price | 29.63 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 636,994 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 120,731,236 |
| Shares Percent Shares Out | 0.0226 |
| Shares Short | 1,116,504 |
| Short Name | Parabilis Medicines, Inc. |
| Short Percent Of Float | 0.0229 |
| Short Ratio | 1.92 |
| Source Interval | 15 |
| State | MA |
| Symbol | PBLS |
| Target High Price | 45.0 |
| Target Low Price | 40.0 |
| Target Mean Price | 41.75 |
| Target Median Price | 41.0 |
| Total Cash | 329,039,008 |
| Total Cash Per Share | 100.473 |
| Total Debt | 53,147,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.77 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 28.351904 |
| Two Hundred Day Average Change | 1.2780952 |
| Two Hundred Day Average Change Percent | 0.045079697 |
| Type Disp | Equity |
| Volume | 636,994 |
| Website | https://parabilismed.com |
| Zip | 2,140 |